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Abstract  1 
Knowledge regarding association of dietary branched chain amino acid (BCAA) and type 2 diabetes 2 
(T2D), and the contribution of BCAA from meat to the risk of T2D are scarce. We evaluated 3 
associations between dietary BCAA intake, meat intake, interaction between BCAA and meat intake 4 
and risk of T2D.Data analyses were performed for 74,155 participants aged 50−79 y at baseline from 5 
the Women's Health Initiative for up to 15 years of follow-up. We excluded from analysis participants 6 
with treated T2D, and factors potentially associated with T2D or missing covariate data. The BCAA 7 
and total meat intake was estimated from food frequency questionnaire (FFQ).  Using Cox proportional 8 
hazards models assessed the relationship between BCAA intake, meat intake, and T2D, adjusting for 9 
confounders. A 20% increment in total BCAA intake (g/day and %energy) was associated with a 7% 10 
higher risk for T2D (HR: 1·07; 95% CI: 1·05-1·09).  For total meat intake, a 20% increment was 11 
associated with a 4% higher risk of T2D (HR: 1·04; 95% CI: 1·03-1·05). The associations between 12 
BCAA intake and T2D were attenuated but remained significant after adjustment for total meat intake. 13 
These relations did not materially differ with or without adjustment for BMI. Our results suggest that 14 
dietary BCAAs and meat intake are positively associated with T2D among postmenopausal women. 15 
The association of BCAA and diabetes risk was attenuated but remained positive after adjustment for 16 
meat intake suggesting that BCAA intake in part but not in full is contributing to the association of 17 
meat with T2D risk.  18 
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INTRODUCTION 19 
Dietary protein, comprised of amino acids, is an important modulator of glucose metabolism, 20 
insulin sensitivity, and, therefore, T2D (1). Higher dietary protein intake has been associated with 21 
reduction in total energy intake and as a result may play a role in therapeutic care for individuals with 22 
obesity-related chronic disease, including T2D (2). Contrary to this evidence, emerging data from 23 
epidemiological studies have suggested a positive association between higher protein and meat intake 24 
and incident T2D (2-7), despite protein’s role in enhancing satiety and diet-induced thermogenesis. The 25 
association of protein intake and risk of T2D has been studied in two large populations that included 26 
thousands of incident T2D cases over 8-12 years of follow-up (6, 8). In particular, in the Women’s 27 
Health Initiative (WHI) (6) study, a ~20% increase in protein intake (corresponding to ~12 g protein and 28 
3·4% energy from protein) was associated with a 5% higher risk of T2D. In the MALMO study (8), in 29 
72,992 women from the Nurses' Health Study, 92,088 women from Nurses' Health Study II and 40,722 30 
men from the Health Professionals Follow-up Study; participants in the highest quintiles of percentage 31 
of energy derived from total protein and animal protein (21·6 % of Energy) had 7% higher risks of T2D 32 
compared with those in the lowest quintiles (14·8 % of Energy). 33 
Of note, a pooled analysis encompassing over four million person-years of follow-up and 34 
15,580 cases of T2D suggested animal protein was associated with higher, whereas vegetable protein 35 
was associated with lower, risk of T2D (8). These results suggest that protein source, in addition to 36 
quantity, may be related to the development of T2D. In fact, higher consumption of meat, particularly 37 
red meat, has been associated with a higher risk of T2D (9). Overall, it is unclear whether it is the 38 
protein or other characteristics (i.e. nutrients, cooking methods) of protein-rich foods which explain the 39 
association with T2D.  40 
One postulated explanation for the differential results is that higher animal protein intake may 41 
result in higher intake of branched chain amino acids (BCAA). BCAAs are essential amino acids that 42 
need to be obtained from diet, which can be found mostly in meat, chicken, fish, dairy products and 43 
eggs (10). BCAAs (leucine, isoleucine and valine) have a critical role in promoting skeletal muscle mass 44 
as well as glucose uptake within the muscle (2, 11). Circulating BCAAs are positively associated with 45 
insulin resistance, as measured by HOMA and Hemoglobin A1c (HbA1C) (12-14).  Recent data from the 46 
Nurses’ Health Studies (I and II) and the Health Professionals Follow-up Study suggest total and 47 
animal protein are associated with higher risk of T2D (8). What is less clear is whether BCAA may be 48 
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systemically elevated in response to an unfavorable and accelerated degradation to these important 49 
diet-derived compounds during a metabolically perturbed state rather than causal in insulin resistance 50 
development.  The purpose of this analysis is to expand upon earlier findings in WHI relating protein 51 
intake to T2D risk by evaluating the associations of BCAA and meat intake and risk of T2D within the 52 
WHI, a large cohort of racially and ethnically diverse postmenopausal women, and the impact of 53 
jointly adjusting for BCAA and meat intake on the risk of T2D. 54 
SUBJECTS AND METHODS 55 
The WHI  56 
The design and baseline descriptions of the WHI studies have been published (15-17). Data for the 57 
present study were selected from the WHI clinical trials (CT) (Dietary Modification, Control Arm 58 
(DM-C), Hormone Therapy, and Calcium/Vitamin D), and WHI observational study (OS). Briefly, 59 
68,132 and 93,676 generally healthy postmenopausal women aged 50–79 y were enrolled in the CT or 60 
the OS at 40 clinical centers across the United States between 1993 and 1998·  61 
Incident T2D during follow-up was documented by self-report at each semiannual contact when 62 
participants were asked by self-administered medical history update questionnaire, “Since the date 63 
given on the front of this form, has a doctor prescribed any of the following pills or treatments?” 64 
Choices included “pills for diabetes” and “insulin shots for diabetes.” Data from a WHI T2D 65 
confirmation study showed that prevalent and incident T2D were consistent (self-reported treated 66 
diabetes was concordant with the medication inventory in 79% of CT, and 77% in the OS participants) 67 
with medication inventories of oral agents or insulin.  Demographic and risk exposure data, as well as 68 
data regarding family and medical history, were obtained by self-report using standardized 69 
questionnaires. WHI-certified staff took physical measurements using standardized equipment, 70 
including blood pressure, height and weight, and blood samples at the clinic visit (15). 71 
Assessment of dietary intake 72 
Dietary intake was estimated using the food frequency questionnaire (FFQ) designed for the 73 
WHI that was administered to all participants at baseline (18). For participants in the dietary 74 
modification trial the baseline FFQ was used for screening eligibility in relation to fat intake and the 75 
intervention arm received support to change diet in a way that would alter meat and BCAA intake. As 76 
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such, in DM women only the control arm year 1 FFQ was used in this analysis of nutrient intake. 77 
Nutrient intake including BCAA content was derived from the USDA nutrient database (19). To 78 
determine total BCAA intake we calculated the sum of isoleucine, leucine and valine consumption 79 
from the usual dietary intake. 80 
Calibration of Dietary Protein Intake  81 
As previously described (6), the WHI-Nutritional Biomarkers Study (WHI-NBS) sub-study 82 
developed biomarker-based calibration equations to reduce measurement error in self-reported intake 83 
of energy and protein by using linear regression models that predicted true intakes of energy and 84 
protein given the self-reported intake and data on study subject characteristics (6).  85 
Baseline (as described above) FFQ energy, BCAAs, and BCAA density served as the 86 
uncalibrated baseline nutrient consumption estimates. For the calibrated energy and protein, logs of 87 
nutrient consumption were obtained directly from the biomarker measurements for the 276 DM-C 88 
women included in the WHI-NBS. For women not in the WHI-NBS, the WHI-NBS calibration 89 
equations were applied (6).  To estimate grams of calibrated BCAA, we multiplied the proportion of 90 
BCAA: total uncalibrated protein in grams by calibrated protein. 91 
Analytic data set 92 
We excluded from analysis participants with treated T2D, i.e., those who reported T2D at enrollment 93 
(n=6447) or during the first year of follow-up for the DM-C (n = 217) to correspond with the FFQ 94 
analysis time points. To align the participant characteristics of the DM-C and other participants for 95 
these analyses, we then applied the following DM trial exclusionary criteria  to all participants in the 96 
analysis sample: breast or colorectal cancer ever (n=5,566),  other cancer (except non-melanoma skin 97 
cancer) within 10 y preceding enrollment (n = 2,667), stroke or acute myocardial infarction 6 months 98 
before enrollment (n = 115), BMI <18 (n =774), hypertension (>200/>105 mm Hg) (n = 224), FFQ 99 
reported daily energy intake of <600 kcal or >5000 kcal) (n =4,706), ≥10 meals prepared away from 100 
home per week (n =4,749), special low-fiber diet (n = 568), special diet due to malabsorption (n = 510), 101 
and unintentional weight loss of >15 lb (6·8 kg) in the 6 months preceding baseline (n = 486) 102 
(Supplemental figure 1).  Finally, 17,518 participants were excluded with missing model covariate 103 
data.  After the above exclusion criteria were applied and the participants with complete data were 104 
selected, the analytic data set included 32,024 CT and 62,241 OS participants.  The WHI and NBS 105 
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protocol and consent forms were approved by the Institutional Review Board for each participating 106 
institution and the Clinical Coordinating Center (Fred Hutchinson Cancer Research Center, Seattle, 107 
WA).  108 
Statistical Analysis 109 
We performed a secondary analysis using subsample of WHI CT and OS data. Demographic 110 
and health characteristics are reported by quintile of baseline total BCAA intake (sum of valine, 111 
leucine, and isoleucine), as estimated from the FFQ.  Accompanying p-values for trend derived from 112 
either linear (continuous, ordinal demographics) or logistic (dichotomous) regression models with the 113 
demographic of interest as a function of linear trend over quintiles (quintile 1 = 1, quintile 2 = 2, etc.).  114 
Follow-up times started with the dietary modification comparison at year 1 or the OS at year 3 and 115 
continued to the earliest of treated diabetes, death, or loss to follow-up (6). 116 
For analysis, BCAA intake was characterized as absolute (g/day), relative to energy intake (% 117 
energy/day), and relative to protein intake (% protein/day). Using Cox proportional hazards models, the 118 
relationship between BCAA intake (modelled continuously for a 20 percent increase and categorically 119 
by quintiles) and T2D is reported by hazard ratio (HR) and the corresponding 95% confidence intervals 120 
(CI).   To be comparable with our prior analysis (6), the final model was adjusted for age, race/ 121 
ethnicity, BMI, education, income, history of CHD, current smoking, current alcohol use, physical 122 
activity, hypertension, family history of T2D, hormone use, glycemic load, glycemic index, and total 123 
energy intake.   Models were additionally stratified within the model by the hormone therapy arms and 124 
5-year age groups.  Trend p-values across quintiles are computed from separate proportional hazards 125 
models with the outcome of interest as a function of linear trend over quintiles.  Similarly, we assessed 126 
associations between meat intake and T2D, as categorized by My Pyramid Equivalents Database 127 
(MPED) categories. In sensitivity analyses, we further adjusted BCAA intake for total meat intake and 128 
omitted adjusting for BMI. 129 
Results 130 
Higher BCAA intake was associated with younger age, measures of socioeconomic status 131 
(white race, higher education and higher income per year), less likely to report current smoking, greater 132 
physical activity, and lower history of CHD (Table 1).  Yet, higher BCAA intake was also associated 133 
with higher BMI and alcohol use, and higher glycemic load. 134 
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Geometric mean uncalibrated BCAA intake in our study was 10·9 g/d comprised of leucine (4·9 135 
g/ d), isoleucine (2·8 g/ d) and valine (3·2 g/ d) (Supplemental Table 1). Major reported meat sources 136 
of BCAAs were red meat (1·2g/day) and poultry (0·78 g/day) in our study population (Supplemental 137 
Table 1). Supplemental table 2 shows the quintile and median values for uncalibrated and calibrated 138 
BCAA variables, and the quintile and median values of major reported food sources for meat intake are 139 
presented in supplemental table 3· 140 
A 20% increment in total BCAA intake (g/day and %energy) was associated with a 7% higher 141 
risk for T2D (HR: 1·07; 95% CI: 1·05, 1·09) (Table 2). Similarly, a 20% increment in intake (g/d and 142 
% of energy) for each of the BCAAs, including leucine, isoleucine and valine was associated with 7% 143 
higher risk of T2D with similar HR: 1·07 (95% CI: 1·05, 1·09). Inferences were similar when 144 
characterizing total BCAA intake as percent of protein intake, although isoleucine was more strongly 145 
associated with T2D risk than leucine or valine (Table 2). For uncalibrated protein, model estimates 146 
were similar with and without adjustment for BMI (Table 2 and Supplemental table 4), while with 147 
calibrated protein the strength of the association was slightly higher with adjustment for BMI 148 
(supplemental table 5 and supplemental table 6). Biomarker-calibration of energy and protein did 149 
not appreciably affect the results (Supplemental table 5).  150 
Likewise, in categorical analyses (Table 2), women reporting intake in the highest quintile of 151 
uncalibrated BCAA (grams/day) had a 35% greater risk of T2D (HR 1·35, 95% CI 1·21, 1·50) 152 
compared to those in the lowest quintile of intake.  When the highest quintiles of uncalibrated protein 153 
expressed as %energy/day (HR 1·21 95% CI 1·13, 1·29) or as a percentage of total protein intake (HR 154 
1·08, 95% CI 1·01, 1·14) were compared to the lowest quintiles, the strength of the association was 155 
attenuated, but remained significant (Table 2). 156 
For total meat intake, a 20% increment increase was associated with a 4% higher risk of T2D 157 
(HR: 1·04; 95% CI: 1·03, 1·05) (Table 3). Risk varied little across animal protein sources, although it 158 
was lower in relation to fish and poultry intake compared to red meat.  A 20% increment increase in 159 
intake of red meat, fish, poultry and processed meat was associated with 3%, 2%, 1%, and 3% higher 160 
risk of T2D, respectively (Table 3). In models jointly adjusted for BCAA and total meat intake, the 161 
associations between BCAA intake (grams) and T2D were attenuated but retained significance (Table 162 
2, and supplemental table 7). 163 
9 
 
Discussion 164 
This study demonstrated that higher BCAA intake, with and without biomarker calibration of 165 
protein exposure estimates, was associated with higher risk of T2D in the WHI OS and CT population. 166 
Our results suggest that increased intake of dietary BCAAs may contribute to the risk of future T2D in 167 
postmenopausal women. In addition to the prospective association with risk of T2D, our findings 168 
showed that total meat intake was associated with increased risk of T2D in postmenopausal women. 169 
The association of meat intake with T2D risk was attenuated in models jointly adjusted for BCAA 170 
intake, but remained significant. These relations did not materially change with or without adjustment 171 
for BMI.  172 
Absolute intakes of total BCAAs in WHI women were similar to those of previous US cohorts 173 
(medians across quintiles 1 through 5 were 10·1 -15·1 g/d in the Nurses’ Health Study I, 12·0-18·0 174 
g/day in the Nurses’ Health Study II, and 12·6-18·8 for in the Health Professionals Follow-up Study 175 
~12·6) (20). To provide perspective on how these ranges relate to dietary intake, four ounces of ground 176 
beef contain 4·0 g BCAA and four chicken tenders contain 1·8g BCAA. 177 
Studies that have examined the association of dietary BCAA consumption with T2D are scarce. 178 
Our results corroborate those of the recent study by Zheng et al. (20) which included three large, 179 
prospective cohorts of US men and women, and reported that  long-term consumption of BCAAs, 180 
individually or in sum, was associated with increased risk of incident T2D. These associations were 181 
independent of traditional diabetes risk factors, including BMI. 182 
 However, in a Japanese cohort (n=13,525), BCAA as a proportion of total protein (17·23% and 183 
17·32% in men and women, respectively) were inversely associated with T2D in women (HR 0·57, 184 
95% CI 0·36 to 0·90 comparing 3rd to 1st tertile), but were not significantly associated with T2D in 185 
men (11).  This could be because of the population age (35 years and older) compared to WHI (50-79 186 
years), the top two sources of BCAA in this population were cereals/potatoes and starches and 187 
fish/shellfish, and the sensitivity and specificity of the T2D ascertainment by self-report compared to 188 
HbA1c was 57·4% and 96·5%, respectively (2, 11). 189 
Some studies of plasma BCAA levels have found associations with insulin resistance, which 190 
may explain the adverse associations of BCAA intake with development of T2D (21, 22). It has been 191 
shown that circulating branched-chain and aromatic amino acid levels predict insulin resistance index 192 
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over 6 years in normoglycemic young adult individuals even when accounting for baseline insulin 193 
resistance (21). In the Framingham Offspring Study, higher plasma BCAA levels were correlated 194 
positively with fasting insulin levels and predicted the future risk of T2D, a finding which was more 195 
pronounced in obese individuals (22). The positive association of plasma BCAA and insulin resistance 196 
has also been found in studies across different settings (13, 23). A review by Newgard et al. (23) concluded 197 
that BCAA and related metabolites are positively associated with insulin resistance and T2D.  In a 198 
metabolomics study, plasma samples from obese and insulin-resistant versus lean and insulin sensitive 199 
subjects were analyzed (14), showing from principal components analysis that most of the variance in 200 
the data were explained by BCAA, which had the strongest association with insulin sensitivity, even 201 
more than the lipid profiles. 202 
Several mechanisms may explain the relationship between BCAA and T2D. Amino acids are 203 
thought to play a significant role in the pathogenesis of insulin resistance, acting as gluconeogenic 204 
precursors and stimulating hexosamine biosynthesis (22). Moreover, amino acid signaling is integrated 205 
by the mammalian target of rapamycin, a nutrient sensor that operates a negative feedback loop toward 206 
insulin receptor substrate 1 signaling, promoting insulin resistance for glucose metabolism (24). Glucose 207 
utilization may also be impaired due to the inhibitory effect of amino acids on glucose transport and 208 
phosphorylation (24). Furthermore, amino acids affect glucose metabolism via stimulation of insulin and 209 
glucagon secretion and by serving as substrates for gluconeogenesis (5). Infusion of amino acids to raise 210 
plasma amino acid concentrations induced insulin resistance in skeletal muscle and stimulated 211 
endogenous glucose production in healthy men (25).  212 
We also observed that higher meat intake increased the risk of T2D by 4% in postmenopausal 213 
women, which is supported by a meta-analysis by Feskens and colleagues (4). The increased risk of 214 
T2D associated with higher meat consumption might be explained in part by meat’s contribution to 215 
BCAA and/or possibly increasing the heme iron load. The BCAAs and tyrosine and phenylalanine are 216 
mainly present in meat and dairy products, although available in many protein-rich foods (26).  For this 217 
analysis, we focused on meat, rather than dairy, sources of BCAA’s, as we were interested in whether 218 
factors other than BCAA’s explained the observed positive association between BCAA with diabetes 219 
risk, and dairy has a weakly protective association with T2D.  The earlier experimental elevations of 220 
plasma amino acids by infusion, resulted in impaired insulin-stimulated glucose disposal and insulin-221 
mediated suppression of (hepatic) glucose production (27).  However, per 100 g of total meat, relative 222 
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risk of T2D increased 15% for (unprocessed) red meat, 13% for poultry, and 4% for processed meat. 223 
Furthermore, higher meat intakes may contribute to increased heme iron load, and iron overload is 224 
associated with increased T2D risk (26). 225 
The current study has important strengths including its prospective design, large sample size, 226 
and long follow-up. Although T2D status, both treated and incident, was assessed by self-report 227 
without adjudication or confirmation by clinical measures, the WHI self-report data for T2D have been 228 
found to be highly consistent with medication use inventories provided by participants (28)owe. It is not 229 
known whether circulating BCAAs are causes/mediators of insulin resistance or by-products of the 230 
associated metabolic dysfunction.  Thus, the present study explored the relation of dietary intake of 231 
BCAAs with T2D, but cannot inform on causality. 232 
Some limitations of the study need to be addressed. Diabetes was assessed using self-report, 233 
which could result in misclassification error.  However, a validation study in the WHI demonstrated 234 
high concordance between self-reported treated diabetes and medication inventories (28).  Although we 235 
controlled for several covariates, measurement error in these constructs may result in residual 236 
confounding; women with higher BCAA intake had higher meat and alcohol intake, were more 237 
educated, had higher income, and higher glycemic load. The role of other BCAA sources, such as 238 
dairy, will be considered in work examining the role of dietary protein sources on diabetes risk within 239 
WHI.  The response to dietary protein content may be dependent on an individual’s degree of 240 
underlying insulin resistance, determined by adiposity and BMI, but in our investigation adjusting for 241 
BMI did not materially changed the associations.  Calibration using urinary nitrogen as a biomarker of 242 
total protein intake was incorporated into the analysis and did not materially change effect estimates in 243 
this analysis, but we did not have corresponding biomarkers of branched chain amino acid intake or 244 
meat intake.  The nutrient database relied on estimation for 26-50% of dietary amino acids, e.g., similar 245 
foods or imputation.  The BCAAs from meat were not able to be separated from total BCAAs.  246 
Because of the observational design, conclusions regarding causality cannot be drawn.  Also, this study 247 
included postmenopausal women aged 50−79 years old from 40 designated clinical sites across, but not 248 
representative of, the U.S. and therefore caution should be taken while generalizing these results to 249 
other populations. Our findings indicated that higher BCAA and meat intakes were associated with 250 
higher risk of T2D. Thus, it may be important to further consider dietary protein sources in dietary 251 
recommendations to prevent T2D. 252 
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Conclusion 253 
In a secondary analysis among a large cohort of postmenopausal women BCAA and meat 254 
intake were associated with higher risk for T2D. The elevation in risk was very modest, but helps to 255 
inform on future guidance for postmenopausal women at elevated risk for T2D. 256 
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Table 1 Characteristics at time of protein measurement1 by quintile of uncalibrated total branched-chain amino acid intake (g/day) * 
Characteristic n=18·971 
Q1: < 7·7 
n=18·629 
Q2: 7·7 – <10·0 
n=19·055 
Q3: 10·0 - 
<12·3 
n=18·446 
Q4: 12·3 - 
<15·3 
n=19·164 
Q5: ≥ 15·3 
P-trend † 
 Means SD Means SD Means SD Means SD Means SD  
Age· mean  64·3 7∙3 64·1 7∙2 63·9 7∙1 63.8 7∙1 63∙4 7·1 <0·001 
Ethnicity §            
     White ‡ 14719 77·6 15853 85·1 16832 88·3 16574 89·9 16907 88·2 0·001 
     Black 2165 11·4 1264 6·8 1025 5·4 520 4·4 995 5·2  
     Hispanic 860 4·5 634 3·4 501 2·6 468 2·5 623 3·3  
     Other / Unknown 1227 6·5 878 4·7 697 3·7 584 3·2 639 3·3  
Education §           <0·001 
     ≤ High school / GED 4865 25·6 4086 21·9 3667 19·2 3512 19·0 3468 18·1  
     School after high school 7408 39·0 7061 37·9 7036 36·9 6650 36·1 7070 36·9  
     College degree or higher 6698 35·3 7482 40·2 8352 43·8 8284 44·9 8626 45·0  
Income §           <0·001 
     ≤ $20·000 3601 19·0 2735 14·7 2497 13·1 2388 12·9 2777 14·5  
     $20·000 - $49·999 8592 45·3 8311 44·6 8412 44·1 8255 44·8 8697 45·4  
     ≥ $50·000 6778 35·7 7583 40·7 8146 42·7 7803 42·3 7690 40·1  
Body Mass Index· kg/m2 §           <0·001 
     Underweight (<18·5) 107 0·6 86 0·5 78 0·4 57 0·3 57 0·3  
     Normal (18·5 - 24·9) 8293 43·7 7616 40·9 7400 38·8 6641 36·0 5600 29·2  
     Overweight (25·0 – 29·9) 6422 33·9 6640 35·6 6843 35·9 6541 35·5 6582 34·3  
     Obese (≥ 30·0) 4149 21·9 4287 23·0 7434 24·8 5207 28·2 692 36·1  
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Current smoker § 1523 8·0 1266 6·8 1205 6·3 1124 6·1 1194 6·2 <0·001 
Current alcohol use § 12550 66·2 13362 71·7 14104 74·0 13640 73·9 13753 71·8 <0·001 
Hormone therapy use §           <0·001 
     Never 8114 42·8 7627 240·9 7771 40·8 7719 41·8 7985 41·7  
     Past 2985 15·7 2935 15·8 2908 15·3 2780 15·1 2957 15·4  
     Current 7872 41·5 8067 43·3 8376 44·0 7947 43·1 8222 42·9  
History of CHD § 582 3·1 523 2·8 501 2·6 427 2·3 442 2·3 <0·001 
History of hypertension § 8346 44·0 7875 42·3 7995 42·0 7782 42·2 8404 43·9 0·770 
Physical activity (METs/wk) 12·5 14·0 13·3 14·8 13·4 13·8 136·6 14·0 13·6 14·2 <0·001 
Total energy intake (kcal) 976·1 238·1 1276·1 252·4 1515·0 282·3 1780·5 322·5 2352·4 574·0 <0·001 
Glycemic Index 52·8 3·9 52·4 3·7 52·2 3·6 51·9 3·6 51·5 3·8 <0·001 
Glycemic load 65·8 23·0 81·0 25·0 93·9 26·9 107·8 30·4 136·1 42·2 <0·001 
Total meat (servings) 1∙7 0∙9 2∙5 1.1 3.0 1.3 3.7 1∙6 5∙0 2∙3 <0·001 
Red meat (servings) 0∙7 0∙5 1∙0 0∙7 1∙2 0∙9 1∙5 1∙0 2∙1 1.5 <0·001 
Fish (servings) 0∙3 0∙3 0∙5 0∙4 0∙5 0∙4 0∙6 0∙5 0∙8 0∙6 <0·001 
Poultry (servings) 0∙4 0∙4 0∙6 0∙5 0∙8 0∙6 0∙9 0∙6 1.2 0∙8 <0·001 
Processed meat (servings) 0∙2 0∙2 0∙3 0∙3 0∙3 0∙3 0∙4 0∙4 0∙6 0∙5 <0·001 
* Baseline (or year 1 for DM trial participants) 
† trend p-value from a linear (continuous and ordinal characteristics) or logistic (dichotomous characteristics) regression model with the 
characteristic of interest as a function of linear trend over the medians of each BCAA quintile. 
‡ p-value trend is based on trend of BCAA quintiles on white ethnicity (yes/no) 
§ frequency  ± % (all such values) 
5Geometric means and standard deviations are presented, with trend tested over log transformed data 
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Table 2 Hazard ratios for the risk of diabetes by quintile of uncalibrated branched-chain amino acid (BCAA) intake 
 Intake (grams) Percent caloric intake Percent protein intake 
 Events Ann% HR (95% CI) * p-value  
† 
Events Ann% HR (95% CI) P Events Ann% HR (95% CI) P-
value 
Total BCAA    <0·001    <0·001    0·02 
Q1 2043 0·88 1·00 (ref)  2083 0·91 1·00 (ref)  2100 0·88 1·00 (ref)  
Q2 vs. Q1 2023 0·86 1·04 (0·97, 1·12)  2186 0·88 1·00 (0·94, 
1·06) 
 2246 0·99 1·05 (0·98, 
1·11) 
 
Q3 vs. Q1 2186 0·90 1·10 (1·02, 1·19)  2209 0·92 1·05 (0·99, 
1·12) 
 2388 0·98 1·05 (0·99, 
1·11) 
 
Q4 vs. Q1 2242 0·95 1·17 (1·07, 1·27)  2315 0·98 1·11 (1·04, 
1·18) 
 2292 0·98 1·07 (1·01, 
1·14) 
 
Q5 vs. Q1 2748 1·15 1·35 (1·21, 1·50)  2449 1·06 1·21 (1·13, 
1·29) 
 2216 0·92 1·08 (1·01, 
1·14) 
 
Continuous ‡   1·07 (1·05, 1·09) <0·001   1·07 (1·05, 
1·09) 
<0·001   1·11 (1·01, 
1·22) 
0·03 
Leucine    <0·001    <0·001    0·01 
Q1 2016 0·88 1·00 (ref)  2124 0·90 1·00 (ref)  2086 0·88 1·00 (ref)  
Q2 vs. Q1 2097 0·87 1·05 (0·98, 1·12)  1998 0·88 1·01 (0·95, 
1·07) 
 2379 1·00 1·06 (1·00, 
1·13) 
 
Q3 vs. Q1 2158 0·89 1·09 (1·00, 1·17)  2167 0·92 1·06 (1·00, 
1·13) 
 2328 0·98 1·05 (0·99, 
1·12) 
 
Q4 vs. Q1 2317 0·96 1·16 (1·06, 1·27)  2505 0·98 1·11 (1·05, 
1·18) 
 2251 0·95 1·06 (1·00, 
1·13) 
 
Q5 vs. Q1 2654 1·15 1·33 (1·19, 1·48)  2448 1·06 1·23 (1·15, 
1·31) 
 2198 0·94 1·09 (1·02, 
1·16) 
 
Continuous ‡   1·07 (1·05, 1·09) <0·001   1·07 (1·05, 
1·09) 
<0·001   1·10 (1·01, 
1·20) 
0·03 
Isoleucine    <0·001    <0·001    <0·001 
Q1 2020 0·87 1·00 (ref)  2066 0·89 1·00 (ref)  1908 0·81 1·00 (ref)  
Q2 vs. Q1 2025 0·87 1·06 (0·99, 1·14)  2175 0·88 1·02 (0·96, 
1·08) 
 2184 0·92 1·04 (0·98, 
1·11) 
 
Q3 vs. Q1 2183 0·90 1·12 (1·03, 1·21)  2169 0·92 1·06 (1·00, 
1·13) 
 2293 0·97 1·06 (1·00, 
1·13) 
 
Q4 vs. Q1 2248 0·95 1·18 (1·08, 1·29)  2286 0·98 1·12 (1·06, 
1·20) 
 2354 0·99 1·09 (1·02, 
1·16) 
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Q5 vs. Q1 2766 1·16 1·38 (1·24, 1·54)  2546 1·09 1·23 (1·16, 
1·31) 
 2503 1·06 1·18 (1·11, 
1·26) 
 
Continuous ‡   1·07 (1·05, 1·09) <0·001   1·07 (1·05, 
1·09) 
<0·001   1·27 (1·15, 
1·40) 
<0·001 
Valine    <0·001    <0·001    0·80 
Q1 2062 0·90 1·00 (ref)  2052 0·91 1·00 (ref)  2188 0·95 1·00 (ref)  
Q2 vs. Q1 2034 0·86 1·02 (0·95, 1·10)  2284 0·91 1·04 (0·98, 
1·11) 
 2362 1·00 1·00 (0·95, 
1·07) 
 
Q3 vs. Q1 2232 0·91 1·09 (1·01, 1·18)  2025 0·92 1·05 (0·99, 
1·12) 
 2328 0·99 1·02 (0·96, 
1·08) 
 
Q4 vs. Q1 2226 0·94 1·12 (1·03, 1·23)  2381 0·97 1·11 (1·05, 
1·19) 
 2311 0·97 1·05 (0·98, 
1·11) 
 
Q5 vs. Q1 2688 1·14 1·30 (1·17, 1·45)  2500 1·05 1·23 (1·15, 
1·31) 
 2053 0·85 0·98 (0·92, 
1·05) 
 
Continuous ‡   1·07 (1·05, 1·09) <0·001   1·07 (1·05, 
1·09) 
<0·001   0·98 (0·90, 
1·07) 
0·62 
* Hazard ratios and confidence intervals from proportional hazards models with incident diabetes as a function of the protein variable of interest adjusted 
for age, ethnicity, BMI, education, income, history of CHD, current smoking, current alcohol use, physical activity, hypertension, family history of 
diabetes, hormone use, glycemic load, glycemic index, and total energy intake. Models are additionally stratified within the model for WHI intervention 
arms and 5-year age groups  
†p-values for categorical protein variables are from a separate model looking at linear trend over the medians of each quintile.  
‡ Hazard ratios, confidence intervals, and p-values in the continuous models for a 20% increase of the protein value of interest 
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Table 3 Hazard ratios for the risk of diabetes by quintile of meat intake by MPED categories (adjusted for 
BMI). 
 Events Ann% HR (95% CI) * P-value † 
Total Meat    <0·001 
   Q1 1707 0·72 1·00 (ref)  
   Q2 vs. Q1 2045 0·87 1·12 (1·05, 1·19)  
   Q3 vs. Q1 2222 0·91 1·15 (1·07, 1·22)  
   Q4 vs. Q1 2321 0·99 1·16 (1·08, 1·24)  
   Q5 vs. Q1 2947 1·27 1·28 (1·19, 1·38)  
   Continuous ‡   1·04 (1·03, 1·05) <0·001 
Red meat    <0·001 
   Q1 1744 0·74 1·00 (ref)  
   Q2 vs. Q1 2095 0·87 1·08 (1·01, 1·15)  
   Q3 vs. Q1 2178 0·92 1·10 (1·03, 1·17)  
   Q4 vs. Q1 2391 1·01 1·16 (1·08, 1·24)  
   Q5 vs. Q1 2834 1·21 1·19 (1·11, 1·28)  
    Continuous ‡   1·03 (1·02, 1·04) <0·001 
Fish    0·002 
   Q1 2181 0·97 1·00 (ref)  
   Q2 vs. Q1 2184 0·92 0·97 (0·92, 1·03)  
   Q3 vs. Q1 2199 0·93 1·00 (0·95, 1·07)  
   Q4 vs. Q1 2306 0·92 0·99 (0·93, 1·05)  
   Q5 vs. Q1 2372 1·01 1·07 (1·01, 1·14)  
    Continuous ‡   1·02 (1·01, 1·03) 0·001 
Poultry    0·010 
   Q1 1918 0·82 1·00 (ref)  
   Q2 vs. Q1 2200 0·92 1·03 (0·97, 1·10)  
   Q3 vs. Q1 2227 0·96 1·04 (0·98, 1·11)  
   Q4 vs. Q1 2217 0·99 1·06 (1·00, 1·13)  
   Q5 vs. Q1 2680 1·06 1·06 (1·00, 1·13)  
    Continuous ‡   1·01 (1·00, 1·02) 0·010 
Processed meat    <0·001 
   Q1 1624 0·72 1·00 (ref)  
   Q2 vs. Q1 2224 0·85 1·08 (1·02, 1·16)  
   Q3 vs. Q1 2278 0·96 1·13 (1·06, 1·21)  
   Q4 vs. Q1 2436 1·07 1·15 (1·08, 1·23)  
   Q5 vs. Q1 2680 1·16 1·17 (1·10, 1·25)  
    Continuous ‡   1·03 (1·02, 1·04) <0·001 
* Hazard ratios and confidence intervals from proportional hazards models with incident diabetes as a 
function of the food group of interest adjusted for age, ethnicity, education, income, history of CHD, current 
smoking, current alcohol use, physical activity, hypertension, family history of diabetes, hormone use, 
glycemic load, glycemic index, total energy intake, and BMI.   Models are additionally stratified within the 
model for WHI hormone therapy arms and 5-year age groups  
† p-values for categorical food group variables are from a separate model looking at linear trend over the 
medians of each quintile. 
‡ Hazard ratios, confidence intervals, and p-values in the continuous models for a 20% increase of the food 
group value of interest 
 
